Related Experiment Video
Updated: Apr 21, 2026

09:08
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
1.4K
Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita
Hiroaki Iwata1, Elena Pipi1, Nicole Möckel1
1Department of Dermatology, University of Lübeck, Lübeck, Germany.
The Journal of Investigative Dermatology
|October 21, 2014
Abstract
No abstract available in PubMed .

